石家庄医药巨头蔡东晨,又收获一份大单。 2月19日,他签发公告宣布,石药旗下巨石生物已与 Radiance Biopharma签署协议,就抗癌药物SYS6005,达成独家授权协议。 根据协议,蔡东晨团队授予对方在美国、欧盟、英国、加拿大等地开发、商业化该药物的权益,其有望获得的潜在对价,最高可达12.4亿美元,约合90亿人民币。 其中,有1500万美元的首付款,最高1.5亿美元的潜在开发...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.